Please login to the form below

Not currently logged in
Email:
Password:

Arzerra

This page shows the latest Arzerra news and features for those working in and with pharma, biotech and healthcare.

Novartis: pipeline will generate 60 filings in three years

Novartis: pipeline will generate 60 filings in three years

Following after in MS is ofatumumab, a potential rival to Roche’s fast-growing CD20-targeting drug Ocrevus (ocrelizumab) that is already approved to treat blood cancers under the Arzerra (brand

Latest news

More from news
Approximately 9 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    3. Novartis’ OMB-157 is a monthly or 12-weekly subcutaneous formulation of the anti-CD20 monoclonal antibody Arzerra (which is indicated as an intravenous infusion for chronic lymphocytic leukaemia) in

  • European biotech: a new generation of leaders emerges European biotech: a new generation of leaders emerges

    If approved, this would become Genmab’s third product on the market, behind Darzalex and Novartis’ Arzerra.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Option to acquire. 1250. GSK. Novartis. Arzerra [ofatumumab] anti CD20 monoclonal antibody in oncology indications.

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics